DataMeds AI plans peptide compounding expansion via Corexa Health
The company ties the move to a recent FDA policy proposal affecting compounded peptide products.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 16 06:56 ETSource: Yahoo Finance
The wire
- 01DataMeds AI says it will expand into peptide compounding through Corexa Health, citing an FDA policy proposal as the trigger.
- 02Compounding pharmacies and telehealth operators are watching how FDA policy shifts reshape which peptides can be legally compounded.
- 03This is a company announcement; no regulatory filing, product list or timeline has been independently confirmed.
From the source
Read at finance.yahoo.comDataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal
